The pathologic classification of rhabdomyosarcoma (RMS) into embryonal or alveolar subtype is an important prognostic factor guiding the therapeutic protocol chosen for an individual patient. Unfortunately, this classification is not always straightforward, and the diagnostic criteria are controversial in a subset of cases. Ancillary studies are used to aid in the classification, but their potential use as independent prognostic factors is rarely studied. The aim of this study is to identify immunohistochemical markers of potential prognostic significance in pediatric RMS and to correlate their expression with PAX-3/FKHR and PAX-7/FKHR fusion status. A single tissue microarray containing 71 paraffin-embedded pediatric RMSs was immunostained with antibodies against p53, bcl-2, Ki-67, CD44, myogenin, and MyoD1. The tissue microarray and whole paraffin blocks were studied for PAX-3/FKHR and PAX-7/FKHR gene fusions by fluorescence in situ hybridization and reverse transcription-polymerase chain reaction. Clinical follow-up data were available for each patient. Immunohistochemical staining results and translocation status were correlated with recurrence-free interval (RFI) and overall survival (OS) using the Kaplan-Meier method, the log-rank test, and Cox proportional hazard regression. The minimum clinical follow-up interval was 24 months (median follow-up = 57 mo).
R habdomyosarcoma (RMS) is a malignant childhood tumor comprised of neoplastic cells with evidence of skeletal muscle differentiation. The annual incidence of RMS is 4 to 7 per million children 15 years of age or younger and the overall 5-year survival rate is 70%. 2 Prognostic factors are critical for determining the patient's risk of recurrent or progressive disease and for tailoring the appropriate therapy. Overall risk stratification for current therapy is based upon tumor site, resectability, stage, and histologic subtyping as alveolar rhabdomyosarcoma (ARMS) or embryonal rhabdomyosarcoma (ERMS). ARMS is considered more clinically aggressive than ERMS, and may require more intensive therapy, depending upon the other clinical factors. 2, 27 The histologic classification of RMS may be difficult in some cases, 1 which has led to the search for other surrogate markers of ARMS. Some studies have reported the prognostic importance of immunohistochemical expression of various markers such as p53 and MIB-1, but most do not adjust for other adverse prognostic factors by multivariable analysis. 3, 17, 25, 28 Immunohistochemical staining for myogenin and the presence of PAX-3/PAX-7-FKHR fusion genes are useful as markers of ARMS; however, not all cases histologically classified as ARMS will have gene fusions or diffuse immunohistochemical staining for myogenin. It is not known if these ancillary tests have the same prognostic importance as the morphologic diagnosis of ARMS. 1, 7, 9, 13, 15, 24 Specifically, the behavior of fusion-negative, morphologic ARMS has been debated. Some authors argue that molecular classification should be the gold-standard for ARMS diagnosis and that any fusion-negative RMS, regardless of morphologic appearance, should be grouped with ERMS; however, the only published clinical outcomes have demonstrated a prognosis in fusion-negative, morphologic ARMS that is intermediate between PAX-3 and PAX-7 fusion-positive cases. 8, 30 The relative importance of immunohistochemistry and molecular analysis on multivariate analysis adjusting for histology, stage, site, and resectability has not been sufficiently addressed. We studied 71 cases of childhood RMS with clinical follow-up data for the immunohistochemical expression of p53, bcl-2, Ki-67, CD44, myogenin, and MyoD1 and the presence of a PAX-3-FKHR or PAX-7-FKHR translocation by fluorescence in situ hybridization (FISH) and/or reverse transcription-polymerase chain reaction (RT-PCR), controlled for clinical stage, patient age, and tumor histology.
MATERIALS AND METHODS

Patient Samples
The patients were treated at the Emma Kinderziekenhuis and the Free University Hospital of Amsterdam in The Netherlands from 1968 to 1990 and were the subject of a previous report. 34 Seventy-one patients from that study population had reconfirmed diagnoses of RMS and paraffin blocks available from the primary tumor. All patients were treated according to protocols from Societe Internationale d'Oncologie Pediatrique (SIOP). Original glass slides and paraffin blocks were retrieved from archives. Patient follow-up information was obtained from the previous study data, originally obtained from review of patients' registration files.
Histologic Classification
The original hematoxylin and eosin (H&E)-stained slides were reviewed by 3 of the authors (A.H.-M., J.M., and M.vR.). For cases without definite rhabdomyoblasts, the diagnosis of RMS was reconfirmed with immunohistochemistry for desmin, myogenin, and MyoD1 before inclusion in the study. All cases were classified into histologic subtypes of RMS on H&E-stained slides using current International Rhabdomyosarcoma Study Group (IRSG)/Children's Oncology Group (COG) criteria. 22, 26 Dr David Parham kindly reviewed a subset of reclassified cases to ensure consistency with criteria used by COG central review.
Tissue Microarray
The tissue array was constructed using a tissue arrayer (Beecher Instruments, Silver Spring, MD) according to a previously described protocol.
14,21 A 312-core tissue microarray was assembled with archival material from 78 RMS patients, including 71 primary tumors, 21 matched recurrences, and 7 separate recurrences without primary material. Some recurrences were multiple, for a total of 99 RMS specimens. These tumors were represented as 69 triplicate, 3 duplicate, and 27 single 0.6-mm diameter cores taken from representative areas of each block. Other malignant tissues serving as controls included triplicate cores of 9 non-RMS sarcomas, 2 lymphomas, 1 Ewing sarcoma/primitive neuroectodermal tumor, 1 neuroblastoma, 1 Wilms tumor, 1 desmoplastic small round cell tumor, and single cores of 2 non-RMS sarcomas. Six triplicate cores of normal tissues and 7 single cores of placenta also served as controls.
Immunohistochemistry and Scoring
After antigen retrieval, microarray sections were stained with antibodies according to standard protocols for formalin-fixed paraffin-embedded material. Details of immunohistochemistry methods are presented in Table 1 . Each core was scored for p53, Ki-67, and CD44 in the following manner: <5% of staining tumor cells = negative, 5% to 20% of staining tumor cells = weakly positive, and >20% of staining tumor cells = strongly positive. The bcl-2 stain was scored as follows: <5% of staining tumor cells = negative, 5% to 10% of staining tumor cells = weakly positive, and >10% of staining tumor cells = strongly positive. Myogenin and MyoD1 staining were scored as follows: no tumor cells with nuclear staining = negative, <80% of tumor cells with nuclear staining = focal, and >80% of tumor cells with nuclear staining = diffuse. Cutoff values for diffuse myogenin staining were chosen because this extent Actin-234 bp. PCR products were electrophoresed in 2% agarose gel and detected with ethidium bromide under ultraviolet illumination. Cases showing weak or absent b Actin bands were repeated with 5-ug, 0.5-ug, and 0.1-ug total RNA to compensate for degraded RNA or potential PCR inhibitors. Fusion transcripts were cut from the gel, purified with the Qiagen (Valencia, CA) QIAquick Gel Extraction kit, and directly sequenced with the above primers in the forward and reverse directions using the ABI PRISM Dye Terminator Cycle Sequencing Ready Reaction kit with detection on the ABI PRISM 3100-Avant Genetic Analyzer. The electropherograms were edited and analyzed using Chromos software. The sequence was used to confirm PAX-3-FKHR versus PAX-7-FKHR translocations.
FISH
FISH studies were performed on 4-mm thick sections of the tissue microarray using the locus specific identifier FKHR (13q14) dual color break apart rearrangement probe system (Vysis, Downer's Grove, IL) according to the manufacturer's instructions. Briefly, after deparaffinization in Hemo-De, slides were pretreated with immersion in sodium thiocyanate and subsequent protease pretreatment (Paraffin Pretreatment Reagent Kit II, Vysis). Slides were rinsed in ethanol and allowed to dry before application of the probe mixture containing the 2 locus specific identifier DNA probes and the chromosome enumeration probe. Slides were then coverslipped and placed on the HyBrite denaturation/ hybridization system (Vysis). A melting temperature of 801C for 5 minutes was followed by a hybridization temperature of 371C for 16 hours, according to the manufacturer's instructions. Slides were then washed in 2 Â saline sodium citrate/0.3% NP-40, decoverslipped and washed 3 more times in 2 Â saline sodium citrate/ 0.3% NP-40, and allowed to air dry. After application of the DAPI II counterstain (Vysis), slides were recoverslipped and viewed on a fluorescence microscope. One hundred nuclei per core were scored for presence of split signals. Cases with >10% of innumerable nuclei with split signals were considered positive for a translocation. Cores with <85% easily innumerable nuclei, extensively overlapping nuclei, or high levels of background fluorescence noise were excluded from evaluation. For these uninformative cores, FISH was repeated on original donor paraffin section blocks when available. Positive and negative controls were performed for each hybridization from paraffin sections of known fusion-positive and fusion-negative RMS.
Statistical Analysis
Univariable (Kaplan-Meier) analysis of patient survival was performed using WinSTAT software version 2001.1 (www.winstat.com) and S+ version 6.2 (Insightful Corp, Seattle). Overall survival (OS) time was defined as the time between the date of diagnosis and the date of death. Patients still alive were censored at date of last follow-up. Recurrence-free interval (RFI) was defined as the time between the date of diagnosis and the date of tumor recurrence. Patients who did not achieve clinical remission had RFI of 0. Patients with clinical remission without recurrence were censored at the date of last follow-up. The log-rank test was used for comparison of outcomes among patient subsets. Subsequent multivariable analyses were performed using Cox proportional hazards model for survival data with S+ version 6.2 software. For the calculation of P values, age was not categorized, but used linearly. Stage and immunohistochemical results were used as ordinal variables. For survival analyses, immunohistochemical results for bcl-2, CD44, and p53 combined both ''weakly positive'' and ''strongly positive'' as a single ''positive'' variable. For Ki-67 results, ''negative'' and ''weakly positive'' were combined into a single ''negative'' variable. Myogenin and MyoD1 results were analyzed as 3 variables: negative, focal, and diffuse. Depending on the variables used, a maximum of 12 patients were excluded from the multivariable analysis because of 1 or more missing values. No correction was made for multiple testing. Adjusted survival curves were calculated according to the corrected group prognosis method. 23 Table 2 summarizes the characteristics of the 71 primary RMS patients according to histologic subtypes. Twenty-three cases were reclassified using current COG/ IRSG criteria. 22, 26 Three cases, originally called ''embryonal sarcoma,'' were included with the ERMS subgroup and 1 was reclassified as ARMS. Nineteen cases, originally classified as ERMS or RMS-not otherwise specified, were reclassified as ARMS. Most cases reclassified as ARMS were originally diagnosed before the year 1990. These cases typically shared either the solid alveolar variant histology or a subtle alveolar pattern with more cohesive rhabdomyoblasts and thin, inconspicuous septae. Figure 1 demonstrates classic ERMS and ARMS histology and an example of a subtler pattern of ARMS typical of reclassified cases.
RESULTS
Histologic Classification and Patient Characteristics
The majority of the patients were still alive at the end of follow-up (52%). The average follow-up for all patients was 55 months (range: 1 to 229 mo), with a median follow-up for the 38 surviving patients of 96 months (range: 25 to 229 mo). Among surviving patients, 79% had at least 5 years of follow-up. The majority were male (60%), had RMS of the embryonal subtype (54%), and had stage I or II disease according to the Intergroup Rhabdomyosarcoma Study (IRS)-TNM classification (70%). 27 Forty-one percent had a favorable site [orbit, head and neck (nonparameningeal), or genitourinary tract (nonbladder/prostate)], whereas 50% were younger than 6 years of age. Tables 3 and 4 depict the association of histologic classification, sex, age, tumor site, IRS-TNM stage, fusion gene status, and immunohistochemical results with 5-year RFI and 10-year OS. As expected, histologic classification, fusion gene status, tumor site, and IRS-TNM stage were all associated with decreased RFI and OS. Age was weakly associated with OS when stratified as <6 years or Z6 years (P = 0.04), but not when stratified as <1 year, 1 to 9 years, or Z10 years. A total of 51 cases were confirmed to be fusion-positive or fusion-negative by RT-PCR, FISH, or both. All 13 fusion-positive cases were morphologically ARMS, comprising 59% of evaluable ARMS. The presence of a gene fusion was associated with decreased RFI (P = 0.0001) and OS (P = 0.0058) in univariable analysis, but not on multivariable analysis adjusted for IRS-TNM stage, tumor site, age, tumor histology, and myogenin expression.
Immunohistochemical Staining Results
Clustergram analysis of expression patterns of p53, Ki-67, CD44, bcl-2, MyoD1, and myogenin for all primary RMS (Treeview program, written by Micheal Eisen PhD, http://rana.lbl.gov/EisenSoftware.htm) yielded no proteomic signature for expression of these 6 proteins that grouped the cases by histologic type, anatomic site, or molecular status. Immunohistochemical staining results for all antibodies on the tissue microarray cores can be viewed at the accompanying website (http:// tma.stanford.edu/tma_portal/RMS/). Examples of staining patterns for myogenin expression are shown in Figure 2 . On univariable analysis, both bcl-2 (RFI P = 0.037, OS P = 0.036) and myogenin (RFI P = 0.0021, OS P = 0.0028) showed evidence of prognostic significance. However, on multivariable analysis adjusted for IRS-TNM stage, tumor site, age, tumor histology, and translocation status, only myogenin expression remained an independent predictor of RFI (P = 0.034) and OS (P = 0.0069). The adjusted survival curves are shown in The distribution of myogenin staining among the categories negative, focal, and diffuse was 2 of 11 (18%), 9 of 11 (81%), and 0 of 11 for ERMS-favorable and 3 of 22 (14%), 17 of 22 (77%), and 2 of 22 (9%) for ERMSnot otherwise specified. Among all RMSs together, the majority (14/16; 88%) of cases with diffuse myogenin staining were ARMS. However, among ARMS, only 14 of 28 (50%) had the diffuse pattern and 4 of 28 (14%) had no staining. Therefore, although diffuse myogenin expression is clearly associated with ARMS histology, the effect of myogenin on survival is not simply because of identification of the ARMS subtype. Cases with diffuse myogenin expression were more likely to be fusionpositive. ARMS cases were also more commonly CD44 À , with higher rates of bcl-2 and Ki-67 expression compared with ERMS. p53 staining was similar among histologic subtypes. Histologic subtype, tumor site, stage, and molecular results of the cases evaluable for myogenin staining are detailed in Table 5 .
DISCUSSION
The histologic distinctions separating ARMS from ERMS can be subtle and difficult in some cases. Central pathologic review is required in most clinical trials to ensure consistency in classification. The difficulty of this distinction, especially on small biopsies, has led to use of ancillary tests as surrogate markers of the alveolar subtype. Diffuse myogenin staining by immunohistochemistry and/or the presence of a PAX-3/FKHR or PAX-7/FKHR rearrangement are frequently used in this setting because of studies correlating these findings with a classic ARMS histology. 19, 26 Although the prognostic significance of PAX-3/FKHR and PAX-7/FKHR rearrangements has been demonstrated, the prognostic significance of myogenin expression has not been studied as an independent variable. P values from the multivariable analysis (excluding gene fusions) are 0.0014 for myogenin, 0.089 for Ki-67, and 0.24 for bcl2. The P value for gene fusions, adjusted for subtype, site, stage, and myogenin, is 0.89. This effectively only compares the 10 negatives and 13 positives in the ARMS subtype group, as in the other subtypes no gene fusions were found. The recurrence-free interval P value for myogenin adjusted for gene fusions is 0.034. *ERMS-favorable indicates embryonal RMS, subtypes spindle cell, botryoid, and embryonal sarcoma.
wNo prostate or bladder, only favorable genitourinary. zIncluding 2 prostates. yFive-year follow-up not reached. ARMS indicates alveolar rhabdomyosarcoma; ERMS, embryonal rhabdomyosarcoma; H and N, head and neck; IRS, Intergroup Rhabdomyosarcoma Study; NOS, not otherwise specified; RMS, rhabdomyosarcoma.
We found that the extent of myogenin immunohistochemical reactivity (none, <80% of cells, or >80% of cells) is strongly associated with RFI and OS in RMS independent of histologic classification, gene fusion status, age, tumor site, and IRS-TNM stage. After the blinded tumor histology, immunoprofile, and outcome data were correlated, the H&E-stained slides were rereviewed. We found that the morphologically ARMS cases with diffuse, focal, and negative myogenin status were histologically indistinguishable. In contrast, the 2 ERMS cases with diffuse myogenin reactivity did have unusual features. One case showed focal cellular areas in which the diagnosis of ARMS was considered. Because the nuclei in these foci did not have the classic round ''lymphomalike'' cytology of ARMS, it was histologically classified as ERMS. In our experience, this is the most common differential diagnostic dilemma in the classification of RMS. In light of the clinical findings (the head and neck tumor was stage II at diagnosis and had an aggressive clinical course with death after 11 mo), this case may have been, in fact, ARMS. To ensure that a possible misclassification of this case did not significantly affect the results, we performed a multivariate analysis with this patient classified as ARMS. Myogenin still proved significantly associated with survival, independent of histologic subtype, localization, stage, and patient age (P = 0.0069).
The second ERMS case with diffuse myogenin staining had a typical morphology of ERMS except for the presence of rare, intermixed ganglion cells (ie, ectomesenchymoma). 6, 20 This patient presented stage I with a paratesticular mass and was alive at 74 months follow-up. Our results suggest that myogenin may define clinically distinct subsets of patients whose tumors have classically defined ARMS histologic features. In addition, myogenin reactivity may help stratify morphologically ambiguous cases of RMS into high-risk and low-risk groups.
It is not entirely clear why myogenin should be a major prognostic factor in RMS. Both myogenin and MyoD1 are members of the MyoD family of myogenic regulatory factors. The specific role of myogenin in myogenesis has not been completely elucidated, but data suggest one important function is myoblast differentiation. Myogenin expression is related to cell density in vitro, which may explain differential expression between the closely packed cells of ARMS versus the more distant cells of ERMS. 18 Interestingly, despite numerous observations that diffuse myogenin expression correlates with ARMS, myogenin mRNA was not selected as a discriminator between ARMS and ERMS in 3 different gene expression profiling analyses. 8, 16, 32 In our experience, messenger RNA detection does not necessarily always correlate with protein expression by immunohistochemistry.
Fusion-negative morphologic ARMS is a poorly understood entity. Forty-one percent of our evaluable ARMS cases lacked a PAX-FKHR gene fusion. This percentage of fusion-negative ARMS is higher than the 25% reported by the IRSG in studies of PCR on frozen tumor samples. 30 This difference could be because of the limitation of samples in a retrospective analysis or possibly because of changes in the histologic definition of ARMS that have occurred over the past decade. 26 We do not believe this difference is because of an overdiagnosis of ARMS in our study because our histologic classification remained prognostically significant on univariate analysis and we rereviewed a subset of reclassified cases with an IRS member to ensure consistency of criteria. As seen in Figure 6 , the clinical outcome of fusion-negative histologic ARMS was more similar to fusion-positive histologic ARMS than ERMS. Fusion-positive and fusion-negative ARMS both had cases with and without diffuse myogenin expression. Therefore, diffuse myogenin expression is not simply a result of a PAX-FKHR fusion gene.
The most recent approach to classifying RMS is gene expression analysis. A genetic signature for fusionpositive ARMS has been identified, and the immunohistochemical expression of some of those proteins can differentiate ARMS from ERMS. 8, 16, 32, 33 Unfortunately, we still do not know the relative importance of these findings as multivariate analyses adjusting for histology, stage, site, and resectability were not performed. Myogenin was not identified as a discriminant in these studies. Our data suggest the significance of myogenin expression may be in prognosis independent of histologic or molecular classification, which would not have been identified by the methodology used in these gene array studies.
Our observations are limited by the fact that this is a retrospective analysis, and some component studies were limited by the availability of tissue blocks 4 ; however, the strength of the results suggest myogenin is a viable prognostic marker in pediatric RMS. Especially as immunohistochemistry is more available worldwide than molecular testing, we assert that myogenin expression might be more useful in some countries. As stated previously, purely molecular classifications have been proposed, but there is no study that clearly demonstrates prognostic significance in a multivariate analysis adjusted for known prognostic factors including histology. 8 Another obvious limitation in this study is the percentage of cases that were morphologically changed from an initial protocol diagnosis of ERMS to ARMS. This set of patients would be deemed under treated by current criteria, which could obviously affect the outcome in this group. However, there were equal numbers of diffuse myogenin-positive cases as nondiffuse myogeninpositive cases in this subgroup.
We do not suggest that myogenin immunohistochemistry immediately replace current standards for the diagnosis of aggressive forms of RMS; however, the demonstrated prognostic strength of myogenin status argues that myogenin immunohistochemistry should be evaluated as an independent variable in analyses of other large cooperative group clinical trials, and ultimately in a prospective setting if our results are confirmed. Otherwise, its potential prognostic independence from histology and PAX translocation status may not be fully known. This information is critical as the diagnostic criteria for identifying clinically aggressive tumors evolve.
The other markers evaluated in this study did not show independent prognostic significance. We found evidence of an association between expression of the apoptosis inhibiting factor bcl-2 in >5% of tumor cells and both RFI and OS in univariable analysis, but not after adjustment for patient age, tumor site, histologic classification, and IRS-TNM stage. Other authors have reported no association of bcl-2 expression with histologic classification or outcome in orbital RMS. 5, 31 In view of the number of factors analyzed and the moderately sized P values, this may be a false-positive finding. Although other studies have reported CD44, Ki-67 and p53 expression to be prognostically relevant in univariable analysis, 3, 11, 28 we found no significant association between expression of CD44, Ki-67, p53, and MyoD1 with RFI and OS. These differences may also be because of the relatively small numbers of patients in the respective studies. We also confirmed previous observations that CD44 expression is more common in ERMS than ARMS. 11, 29 In conclusion, our data suggest for the first time that diffuse myogenin expression by immunohistochemistry is prognostically relevant in RMS, independent of histology. Cases with diffuse myogenin staining in this study included a mixture of cases with and without a demonstrable gene fusion. ARMS cases with less myogenin expression had a less aggressive clinical course. Immunohistochemical expression of myogenin could be easily adopted in routine practice and is more accessible worldwide than molecular analysis. With standardization of laboratory protocols, myogenin immunoreactivity could potentially provide a more reproducible variable for risk stratification in international collaborative group studies and deserves evaluation as an independent variable in future prospective trials.
